PAR003 was meant to start at beginning of H2 this year.
Now PAR are saying they will consult with FDA in H2 this year on endpoints for 003 for DMOAD label.
Significant program delays. Pity there wasn’t significant difference in WOMAC scores at six months.
- Forums
- ASX - By Stock
- PAR
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-80
-
- There are more pages in this discussion • 307 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M |
Open | High | Low | Value | Volume |
27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 17420 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.300 |
2 | 54067 | 0.295 |
2 | 6448 | 0.290 |
2 | 60208 | 0.285 |
2 | 100000 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 17420 | 5 |
0.315 | 112073 | 3 |
0.320 | 120163 | 4 |
0.325 | 3050 | 2 |
0.330 | 29123 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
PAR (ASX) Chart |